phrykt

Regeneron Pharmaceuticals, Inc. (REGN): who owns it and who trades it

As of Nov 16, 2026, REGN insiders reported 134 open-market sales worth $57.9M and no purchases in the last 12 months, with 25% of the sale value made under pre-set 10b5-1 plans. The largest seller was George L Sing (Director), with $20.4M. 10 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Regeneron Pharmaceuticals

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns REGN

1,330 funds and institutions reported REGN shares worth $57.7B at the end of Q2 2026. The largest holder is BlackRock, Inc. with $5.7B.

10 largest owners, by value

BlackRock, Inc.$5.7B
Vanguard Capital Management LLC$4.1B
Dodge & Cox$3B
State Street Corp$3B
Invesco Ltd.$2.5B
JPMorgan Chase & Co$2.4B
Vanguard Portfolio Management LLC$2B
Franklin Resources Inc$1.7B
Geode Capital Management, LLC$1.6B
Nuveen, LLC$1.3B

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.9.11M–$5.7B+2%
Vanguard Capital Management LLC6.63M–$4.1B-0%
Dodge & Cox4.87M–$3B+9%
State Street Corp4.83M–$3B+4%
Invesco Ltd.3.94M–$2.5B+129%
JPMorgan Chase & Co3.77M–$2.4B–
Vanguard Portfolio Management LLC3.18M–$2B+85%
Franklin Resources Inc2.77M–$1.7B+2%
Geode Capital Management, LLC2.63M–$1.6B+1%
Nuveen, LLC2.02M–$1.3B-2%
Loomis Sayles & Co L P1.86M–$1.2B-3%
T. Rowe Price Associates1.53M–$954M-30%
Morgan Stanley1.40M–$872M+6%
Bank of America Corp1.29M–$805M+9%
Wellington Management Group LLP1.27M–$792M-31%
Norges Bank1.17M–$731M–
Goldman Sachs Group Inc1.16M–$725M-11%
AQR Capital Management LLC1.13M–$702M-9%
Amundi1.01M–$632M+0%
Northern Trust Corp916,467–$571M-3%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, REGN insiders reported $0 of open-market purchases and $57.9M of sales. 25% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$57.9M
134 trades, 11 people
Sales under a 10b5-1 plan
25%
Share of sale value
Latest trade
Nov 4, 2026
Filed Nov 6, 2026

Purchases and sales by month

$43.3M$43.3MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 4, 2026Jason PitofskyVice presidentSale439$939.57$412KForm 4
Nov 4, 2026Jason PitofskyVice presidentSale575$940.46$541KForm 4
Nov 4, 2026Jason PitofskyVice presidentSale982$941.58$925KForm 4
Nov 4, 2026Jason PitofskyVice presidentSale1,215$942.31$1.1MForm 4
Nov 4, 2026Jason PitofskyVice presidentSale529$943.53$499KForm 4
Nov 4, 2026Jason PitofskyVice presidentSale108$944.22$102KForm 4
Nov 4, 2026Jason PitofskyVice presidentSale35$945.61$33.1KForm 4
Nov 4, 2026Jason PitofskyVice presidentSale179$950.76$170KForm 4
Nov 3, 2026Huda Y ZoghbiDirectorSale6,939$970.42$6.7MForm 4
Nov 3, 2026Huda Y ZoghbiDirectorSale500$971.06$486KForm 4
Nov 2, 2026Joseph J LarosaVice presidentSale3,939$965.41$3.8MForm 4
Nov 2, 2026Joseph J LarosaVice presidentSale527$966.11$509KForm 4
Nov 2, 2026Christine A PoonDirectorSale218$966.74$211KForm 4
Nov 2, 2026Christine A PoonDirectorSale772$967.38$747KForm 4
Nov 2, 2026Christine A PoonDirectorSale2,499$968.58$2.4MForm 4
Nov 2, 2026Christine A PoonDirectorSale3,203$969.50$3.1MForm 4
Nov 2, 2026Christine A PoonDirectorSale937$970.51$909KForm 4
Nov 2, 2026Christine A PoonDirectorSale201$971.31$195KForm 4
Nov 2, 2026George L SingDirectorSale1,224$960.57$1.2MForm 4
Nov 2, 2026George L SingDirectorSale540$961.85$519KForm 4
Nov 2, 2026George L SingDirectorSale2,522$962.61$2.4MForm 4
Nov 2, 2026George L SingDirectorSale4,338$963.47$4.2MForm 4
Nov 2, 2026George L SingDirectorSale2,670$964.57$2.6MForm 4
Nov 2, 2026George L SingDirectorSale7,073$965.38$6.8MForm 4
Nov 2, 2026George L SingDirectorSale1,522$966.27$1.5MForm 4
Nov 2, 2026George L SingDirectorSale1,040$967.07$1MForm 4
Nov 2, 2026George L SingDirectorSale200$970.18$194KForm 4
Oct 30, 2026Michael S BrownDirectorSale plan1,929$875.00$1.7MForm 4
Oct 30, 2026Kathryn GuariniDirectorSale plan400$900.00$360KForm 4
Oct 30, 2026Marion McCourtVice presidentSale plan1,132$869.43$984KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan6$753.76$4.5KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan35$755.91$26.5KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan16$757.68$12.1KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan24$758.16$18.2KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan14$759.96$10.6KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan74$760.65$56.3KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan27$761.36$20.6KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan55$762.57$41.9KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan25$763.76$19.1KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan219$764.40$167KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan271$765.39$207KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan279$766.47$214KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan192$767.39$147KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan105$768.33$80.7KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan127$769.30$97.7KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan12$770.20$9.2KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan283$771.56$218KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan211$772.56$163KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan224$773.40$173KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan121$774.48$93.7KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan376$775.46$292KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan66$776.31$51.2KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan38$777.76$29.6KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan454$778.64$354KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan380$779.59$296KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan463$780.63$361KForm 4
Oct 14, 2026Andrew J MurphyCo-Chief Scientific OffiSale plan50$781.47$39.1KForm 4
Sep 3, 2026Marion McCourtVice presidentSale plan1,131$857.39$970KForm 4
Sep 2, 2026Marion McCourtVice presidentSale plan1,215$850.00$1MForm 4
Sep 2, 2026Kathryn GuariniDirectorSale plan400$850.00$340KForm 4
Aug 10, 2026Kathryn GuariniDirectorSale plan400$800.00$320KForm 4
Aug 10, 2026Huda Y ZoghbiDirectorSale plan800$800.00$640KForm 4
Jul 2, 2026Arthur F RyanDirectorSale plan200$650.15$130KForm 4
May 1, 2026Arthur F RyanDirectorSale plan2$710.87$1.4KForm 4
May 1, 2026Arthur F RyanDirectorSale plan5$711.49$3.6KForm 4
May 1, 2026Arthur F RyanDirectorSale plan1$712.09$712Form 4
May 1, 2026Arthur F RyanDirectorSale plan2$714.13$1.4KForm 4
May 1, 2026Arthur F RyanDirectorSale plan4$707.40$2.8KForm 4
May 1, 2026Arthur F RyanDirectorSale plan6$709.45$4.3KForm 4
May 1, 2026Arthur F RyanDirectorSale plan7$706.74$4.9KForm 4
May 1, 2026Arthur F RyanDirectorSale plan14$705.56$9.9KForm 4
May 1, 2026Arthur F RyanDirectorSale plan15$704.28$10.6KForm 4
May 1, 2026Arthur F RyanDirectorSale plan24$703.46$16.9KForm 4
May 1, 2026Arthur F RyanDirectorSale plan5$701.76$3.5KForm 4
May 1, 2026Arthur F RyanDirectorSale plan15$702.46$10.5KForm 4
Apr 1, 2026Arthur F RyanDirectorSale plan13$776.62$10.1KForm 4
Apr 1, 2026Arthur F RyanDirectorSale plan9$777.42$7KForm 4
Apr 1, 2026Arthur F RyanDirectorSale plan4$778.24$3.1KForm 4
Apr 1, 2026Arthur F RyanDirectorSale plan40$779.71$31.2KForm 4
Apr 1, 2026Arthur F RyanDirectorSale plan14$775.58$10.9KForm 4
Apr 1, 2026Arthur F RyanDirectorSale plan8$773.59$6.2KForm 4
Apr 1, 2026Arthur F RyanDirectorSale plan3$772.76$2.3KForm 4
Apr 1, 2026Arthur F RyanDirectorSale plan1$771.32$771Form 4
Apr 1, 2026Arthur F RyanDirectorSale plan8$774.58$6.2KForm 4
Mar 2, 2026Arthur F RyanDirectorSale plan20$788.96$15.8KForm 4
Mar 2, 2026Arthur F RyanDirectorSale plan2$787.34$1.6KForm 4
Mar 2, 2026Arthur F RyanDirectorSale plan7$786.61$5.5KForm 4
Mar 2, 2026Arthur F RyanDirectorSale plan11$785.48$8.6KForm 4
Mar 2, 2026Arthur F RyanDirectorSale plan2$781.21$1.6KForm 4
Mar 2, 2026Arthur F RyanDirectorSale plan10$783.62$7.8KForm 4
Mar 2, 2026Arthur F RyanDirectorSale plan2$782.62$1.6KForm 4
Mar 2, 2026Arthur F RyanDirectorSale plan7$777.46$5.4KForm 4
Mar 2, 2026Arthur F RyanDirectorSale plan2$778.30$1.6KForm 4
Mar 2, 2026Arthur F RyanDirectorSale plan5$779.69$3.9KForm 4
Mar 2, 2026Arthur F RyanDirectorSale plan3$780.69$2.3KForm 4
Mar 2, 2026Arthur F RyanDirectorSale plan20$789.28$15.8KForm 4
Mar 2, 2026Arthur F RyanDirectorSale plan9$784.48$7.1KForm 4
Feb 19, 2026Huda Y ZoghbiDirectorSale plan4$790.00$3.2KForm 4
Feb 19, 2026Huda Y ZoghbiDirectorSale plan160$784.45$126KForm 4
Feb 19, 2026Huda Y ZoghbiDirectorSale plan56$785.61$44KForm 4

Latest 100 of 134 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
George L SingDirector–$20.4MNov 2, 2026
Huda Y ZoghbiDirector–$9.1MNov 3, 2026
Christine A PoonDirector–$7.6MNov 2, 2026
Jason PitofskySVP Controller–$5.4MNov 4, 2026
Joseph J LarosaEVP General Counsel and Secret–$4.3MNov 2, 2026
Andrew J MurphyCo-Chief Scientific Officer–$3.2MOct 14, 2026
Marion McCourtEVP Commercial–$3MOct 30, 2026
Bonnie L BasslerDirector–$1.8MJan 7, 2026
Michael S BrownDirector–$1.7MOct 30, 2026
Kathryn GuariniDirector–$1MOct 30, 2026
Arthur F RyanDirector–$435KJul 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

REGN short interest

2.22M REGN shares are sold short. Over the last 12 reports the number of shares short went down 20%.

As of Oct 30, 2026, 2.22M REGN shares were sold short, up 3.8% from the report before. At the average daily volume of 810,850 shares, buying them all back would take about 2.7 trading days (days to cover).

Shares short

2.22MMay 15Oct 303.71M

Days to cover

2.7May 15Oct 305.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.22M–+4%810,8502.7
Oct 15, 20262.13M–-1%670,7143.2
Sep 30, 20262.15M–-15%863,8422.5
Sep 15, 20262.53M–-1%571,2714.4
Aug 31, 20262.55M–+7%662,8643.9
Aug 14, 20262.40M–-29%760,6543.1
Jul 31, 20263.39M–-3%858,6623.9
Jul 15, 20263.50M–+0%741,2244.7
Jun 30, 20263.49M–+6%1.20M2.9
Jun 15, 20263.30M–+10%968,6903.4
May 29, 20263.00M–+8%1.53M2.0
May 15, 20262.78M–-15%764,0413.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded REGN

Since Nov 17, 2024, 8 members of Congress reported 5 purchases and 9 sales of REGN. The latest was a sale by Gilbert Ray Cisneros, Jr. on May 15, 2026, reported Jun 8, 2026.

Purchases 5Sales 9

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
May 15, 2026Gilbert Ray Cisneros, Jr. (D-CA)Sale$1K–$15KSelfJun 8, 2026Report
Mar 27, 2026Alan Armstrong (R-OK)Purchase$1K–$15KSelfJul 21, 2026Report
Feb 12, 2026Julia Letlow (R-LA)Purchase$1K–$15KSelfMar 12, 2026Report
Nov 18, 2025Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfDec 15, 2025Report
May 15, 2025Robert P. Bresnahan, Jr. (R-PA)Purchase$1K–$15KSelfJun 9, 2025Report
Apr 10, 2025Byron Donalds (R-FL)Sale$1K–$15KSelfMay 24, 2025Report
Apr 10, 2025Byron Donalds (R-FL)Sale$1K–$15KSpouseMay 24, 2025Report
Apr 8, 2025Robert P. Bresnahan, Jr. (R-PA)Sale$1K–$15KSelfMay 8, 2025Report
Apr 7, 2025Jefferson Shreve (R-IN)Sale$15K–$50KSelfMay 8, 2025Report
Apr 1, 2025Julie Johnson (D-TX)Sale$1K–$15KJointMay 14, 2025Report
Feb 25, 2025Robert P. Bresnahan, Jr. (R-PA)Sale$1K–$15KSelfMar 27, 2025Report
Feb 12, 2025Julie Johnson (D-TX)Partial sale$1K–$15KJointMar 12, 2025Report
Jan 24, 2025Josh Gottheimer (D-NJ)Sale$1K–$15KJointFeb 10, 2025Report
Jan 15, 2025Julie Johnson (D-TX)Purchase$1K–$15KJointFeb 12, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Regeneron Pharmaceuticals company events

Regeneron Pharmaceuticals filed 10 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 30, 2026.

  1. Oct 30, 2026ResultsReleased financial results. Filing
  2. Oct 6, 2026AgreementRegeneron Pharmaceuticals, Inc., a New York corporation, Sanofi Biotechnology SAS, a société par actions simplifée organized under the laws of France, and Sanofi, a société anonyme organized under the laws of France, entered into the Sixth Amendment to the Amended and Restated License and… Filing
  3. Sep 30, 2026LeadershipReported a change among its top officers or directors, or their pay. Filing
  4. Jul 30, 2026ResultsReleased financial results. Filing
  5. Jul 6, 2026ResultsReleased financial results. Filing
  6. Jun 17, 2026VoteReported shareholder vote results. Filing
  7. Apr 29, 2026ResultsReleased financial results. Filing
  8. Apr 8, 2026ResultsReleased financial results. Filing
  9. Jan 30, 2026ResultsReleased financial results. Filing
  10. Jan 12, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Regeneron Pharmaceuticals financials

Famous investors that hold REGN

10 of the 50 well-known investors we track reported holding REGN in their latest 13F filing. The largest position is Ken Griffin's, worth $267M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026352,728$267M0.1%+512%
Jim Simons · Renaissance TechnologiesQ3 2026272,218$206M0.3%+84%
Israel Englander · Millennium ManagementQ3 2026147,538$112M0.1%-11%
Steve Cohen · Point72 Asset ManagementQ3 2026124,380$94.3M0.2%New
Ray Dalio · Bridgewater AssociatesQ3 2026105,934$80.3M0.3%+106%
Jeremy Grantham · GMOQ3 202671,076$53.9M0.1%-4%
Paul Tudor Jones · Tudor Investment CorpQ3 202637,604$28.5M0.1%New
Lee Ainslie · Maverick CapitalQ3 20261,824$1.4M0.0%New
Richard Pzena · Pzena Investment ManagementQ3 2026409$310K0.0%New
Ken Fisher · Fisher Asset ManagementQ3 2026347$264K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Regeneron Pharmaceuticals, Inc. (REGN) stock

Who owns the most REGN stock?

The largest reported owner of Regeneron Pharmaceuticals, Inc. (REGN) is BlackRock, Inc.. In total, 1,330 funds and institutions reported holding REGN at the end of Q2 2026. See the largest owners.

Are REGN insiders buying or selling?

In the last 12 months, REGN insiders reported no open-market purchases and 134 sales worth $57.9M. The latest trade was on Nov 4, 2026. See every trade.

What is the short interest in REGN?

As of Oct 30, 2026, 2.22M REGN shares were sold short, up 3.8% from the report before. At the average daily volume of 810,850 shares, buying them all back would take about 2.7 trading days (days to cover). See the history.

Have members of Congress traded REGN?

Yes. 8 members of Congress reported 5 purchases and 9 sales of REGN since Nov 17, 2024. The latest was reported on Jul 21, 2026. See the trades.

Which famous investors hold REGN?

10 of the 50 well-known investors we track reported REGN in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $267M. See all holders.

Executive pay

Regeneron Pharmaceuticals's chief executive was paid a total of $7.3M for the year ended Dec 31, 2025, up 7% from $6.8M the year before. In the last 12 months, Regeneron Pharmaceuticals's executives and directors bought no stock on the open market and sold $57.9M.

Chief executive, total pay$7.3MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$39MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$7.7MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.